172 related articles for article (PubMed ID: 37976135)
1. Silencing of Dicer enhances dacarbazine resistance in melanoma cells by inhibiting ADSL expression.
Yeh YW; Hsu TW; Su YH; Wang CH; Liao PH; Chiu CF; Tseng PC; Chen TM; Lee WR; Tzeng YS
Aging (Albany NY); 2023 Nov; 15(22):12873-12889. PubMed ID: 37976135
[TBL] [Abstract][Full Text] [Related]
2. Adenylosuccinate lyase enhances aggressiveness of endometrial cancer by increasing killer cell lectin-like receptor C3 expression by fumarate.
Park H; Ohshima K; Nojima S; Tahara S; Kurashige M; Hori Y; Okuzaki D; Wada N; Ikeda JI; Morii E
Lab Invest; 2018 Apr; 98(4):449-461. PubMed ID: 29467457
[TBL] [Abstract][Full Text] [Related]
3. Targeting nodal in conjunction with dacarbazine induces synergistic anticancer effects in metastatic melanoma.
Hardy KM; Strizzi L; Margaryan NV; Gupta K; Murphy GF; Scolyer RA; Hendrix MJ
Mol Cancer Res; 2015 Apr; 13(4):670-80. PubMed ID: 25767211
[TBL] [Abstract][Full Text] [Related]
4. Adenylosuccinate lyase is oncogenic in colorectal cancer by causing mitochondrial dysfunction and independent activation of NRF2 and mTOR-MYC-axis.
Taha-Mehlitz S; Bianco G; Coto-Llerena M; Kancherla V; Bantug GR; Gallon J; Ercan C; Panebianco F; Eppenberger-Castori S; von Strauss M; Staubli S; Bolli M; Peterli R; Matter MS; Terracciano LM; von Flüe M; Ng CKY; Soysal SD; Kollmar O; Piscuoglio S
Theranostics; 2021; 11(9):4011-4029. PubMed ID: 33754045
[No Abstract] [Full Text] [Related]
5. Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy.
Lev DC; Ruiz M; Mills L; McGary EC; Price JE; Bar-Eli M
Mol Cancer Ther; 2003 Aug; 2(8):753-63. PubMed ID: 12939465
[TBL] [Abstract][Full Text] [Related]
6. Targeting the De Novo Purine Synthesis Pathway Through Adenylosuccinate Lyase Depletion Impairs Liver Cancer Growth by Perturbing Mitochondrial Function.
Jiang T; Sánchez-Rivera FJ; Soto-Feliciano YM; Yang Q; Song CQ; Bhuatkar A; Haynes CM; Hemann MT; Xue W
Hepatology; 2021 Jul; 74(1):233-247. PubMed ID: 33336367
[TBL] [Abstract][Full Text] [Related]
7. MGMT expression levels predict disease stabilisation, progression-free and overall survival in patients with advanced melanomas treated with DTIC.
Busch C; Geisler J; Lillehaug JR; Lønning PE
Eur J Cancer; 2010 Jul; 46(11):2127-33. PubMed ID: 20541396
[TBL] [Abstract][Full Text] [Related]
8. Acid ceramidase expression modulates the sensitivity of A375 melanoma cells to dacarbazine.
Bedia C; Casas J; Andrieu-Abadie N; Fabriàs G; Levade T
J Biol Chem; 2011 Aug; 286(32):28200-9. PubMed ID: 21700700
[TBL] [Abstract][Full Text] [Related]
9. Low BRAF and NRAS expression levels are associated with clinical benefit from DTIC therapy and prognosis in metastatic melanoma.
Birkeland E; Busch C; Berge EO; Geisler J; Jönsson G; Lillehaug JR; Knappskog S; Lønning PE
Clin Exp Metastasis; 2013 Oct; 30(7):867-76. PubMed ID: 23673558
[TBL] [Abstract][Full Text] [Related]
10. Anti-DR5 monoclonal antibody-mediated DTIC-loaded nanoparticles combining chemotherapy and immunotherapy for malignant melanoma: target formulation development and in vitro anticancer activity.
Ding B; Wu X; Fan W; Wu Z; Gao J; Zhang W; Ma L; Xiang W; Zhu Q; Liu J; Ding X; Gao S
Int J Nanomedicine; 2011; 6():1991-2005. PubMed ID: 21976975
[TBL] [Abstract][Full Text] [Related]
11. In-vitro and in-vivo inhibition of melanoma growth and metastasis by the drug combination of celecoxib and dacarbazine.
Sadhu SS; Wang S; Averineni RK; Seefeldt T; Yang Y; Guan X
Melanoma Res; 2016 Dec; 26(6):572-579. PubMed ID: 27540834
[TBL] [Abstract][Full Text] [Related]
12. Comparison of a treatment strategy combining CCI-779 plus DTIC versus DTIC monotreatment in human melanoma in SCID mice.
Thallinger C; Werzowa J; Poeppl W; Kovar FM; Pratscher B; Valent P; Quehenberger P; Joukhadar C
J Invest Dermatol; 2007 Oct; 127(10):2411-7. PubMed ID: 17508024
[TBL] [Abstract][Full Text] [Related]
13. Protocatechuic aldehyde acts synergistically with dacarbazine to augment DNA double-strand breaks and promote apoptosis in cutaneous melanoma cells.
Pei J; Su Z; Zeng X; Zhong Y; Zhang Y; Yang Y; Lu Q; Li J; Deng Y
BMC Complement Med Ther; 2023 Apr; 23(1):111. PubMed ID: 37024907
[TBL] [Abstract][Full Text] [Related]
14. Alteration of dacarbazine pharmacokinetics after interleukin-2 administration in melanoma patients.
Chabot GG; Flaherty LE; Valdivieso M; Baker LH
Cancer Chemother Pharmacol; 1990; 27(2):157-60. PubMed ID: 2249333
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-21 guide and passenger strand regulation of adenylosuccinate lyase-mediated purine metabolism promotes transition to an EGFR-TKI-tolerant persister state.
Zhang WC; Skiados N; Aftab F; Moreno C; Silva L; Corbilla PJA; Asara JM; Hata AN; Slack FJ
Cancer Gene Ther; 2022 Dec; 29(12):1878-1894. PubMed ID: 35840668
[TBL] [Abstract][Full Text] [Related]
16. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG.
Schadendorf D; Ugurel S; Schuler-Thurner B; Nestle FO; Enk A; Bröcker EB; Grabbe S; Rittgen W; Edler L; Sucker A; Zimpfer-Rechner C; Berger T; Kamarashev J; Burg G; Jonuleit H; Tüttenberg A; Becker JC; Keikavoussi P; Kämpgen E; Schuler G;
Ann Oncol; 2006 Apr; 17(4):563-70. PubMed ID: 16418308
[TBL] [Abstract][Full Text] [Related]
17. Mutation of a nuclear respiratory factor 2 binding site in the 5' untranslated region of the ADSL gene in three patients with adenylosuccinate lyase deficiency.
Marie S; Race V; Nassogne MC; Vincent MF; Van den Berghe G
Am J Hum Genet; 2002 Jul; 71(1):14-21. PubMed ID: 12016589
[TBL] [Abstract][Full Text] [Related]
18. [Hypersensitivity to dacarbazine in patients with metastatic malignant melanoma].
Levy A; Guitera P; Kerob D; Ollivaud L; Archimbaud A; Dubertret L; Basset-Seguin N
Ann Dermatol Venereol; 2006 Feb; 133(2):157-60. PubMed ID: 16508601
[TBL] [Abstract][Full Text] [Related]
19. Anti-melanoma activity of the 9.2.27PE immunotoxin in dacarbazine resistant cells.
Risberg K; Fodstad O; Andersson Y
J Immunother; 2010 Apr; 33(3):272-8. PubMed ID: 20445347
[TBL] [Abstract][Full Text] [Related]
20. A Caenorhabditis elegans model of adenylosuccinate lyase deficiency reveals neuromuscular and reproductive phenotypes of distinct etiology.
Fenton AR; Janowitz HN; Franklin LP; Young RG; Moro CA; DeGennaro MV; McReynolds MR; Wang W; Hanna-Rose W
Mol Genet Metab; 2023 Nov; 140(3):107686. PubMed ID: 37607437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
